Quick Facts

• Primary Use: Management of chronic insomnia disorder.
• Benefit: May help patients with difficulty falling asleep (sleep onset).
• Benefit: May help patients with difficulty staying asleep (sleep maintenance).

---

What Somnols Treats: Main Uses and Benefits

Somnols is a prescription medication approved for the management of chronic insomnia disorder in adults. It is intended for use in patients experiencing ongoing difficulty with sleep patterns.

The clinical purpose of Somnols is focused on addressing the core symptoms of insomnia. The treatment may be utilized to support patients who experience prolonged time required to fall asleep, a condition known as sleep-onset latency.

Additionally, Somnols may be used to assist with the duration of sleep by helping patients reduce the number of times they awaken after initially falling asleep, or the total time spent awake during the night. The medication is part of a comprehensive approach to sleep health that may include behavioral adjustments.

Consultation with a qualified healthcare professional is necessary to determine if Somnols is an appropriate component of a patient's overall treatment plan.

Regulatory References

1. https://www.nhlbi.nih.gov/health/insomnia/treatment

Eligibility scope

Population Status	Classification	Specific Restrictions
Allowed	Adults (ge 18 years)	Approved for short-term insomnia treatment.
Not Recommended	Pediatric Population (le 18 years)	Safety and efficacy have not been established.
Conditional Use	Special Populations	Elderly patients, those with non-severe renal or hepatic insufficiency, chronic respiratory insufficiency, or symptomatic depression.

---

Absolute Contraindications

The medicine is explicitly contraindicated and must not be used in patients with:

• Severe organ impairment (severe hepatic insufficiency, severe respiratory failure).
• Myasthenia gravis (severe muscle weakness) or severe sleep apnoea syndrome.
• Known hypersensitivity to zopiclone or excipients.
• Prior experience of complex sleep behaviors (e.g., sleepwalking) after taking the drug.

---

Pregnancy and Lactation Status

Use is generally not recommended during pregnancy, with specific regulatory restrictions cited for the last trimester due to potential neonatal risks. Routine use is also not recommended for women who are breastfeeding.

The official regulatory documents for Somnols (Zopiclone) define its interaction profile through established pharmacokinetic modulation and pharmacodynamic reinforcement, establishing strict constraints for co-administration.

The combination of Zopiclone with Opioids is assigned a major regulatory warning due to the high risk of profound sedation, respiratory depression, coma, and death. A pharmacodynamic interaction occurs with other Central Nervous System (CNS) Depressants—such as sedatives, antipsychotics, and specific antidepressants—resulting in additive CNS-depressant effects and increased psychomotor impairment. Regulatory guidance formally states that co-administration with Alcohol (Ethanol) is not recommended because it significantly enhances the sedative effect.

Zopiclone’s clearance is subject to pharmacokinetic interference through the CYP3A4 enzyme system. Potent CYP3A4 Inhibitors, including Erythromycin and Ketoconazole, impede metabolism, which significantly increases Zopiclone plasma concentration (exposure) and enhances the hypnotic effect. For instance, Erythromycin is reported to increase Zopiclone AUC by 80%. Conversely, Potent CYP3A4 Inducers, such as Rifampicin, decrease plasma levels, potentially leading to a diminished overall clinical effect. Intake with a heavy, high-fat meal results in slower absorption, which is officially expected to reduce the drug's effect on sleep onset. Official warnings note that interaction risks are heightened for populations with Severe Hepatic Impairment and for the Elderly/Debilitated patient group due to reduced clearance.

How Somnols Works

Targeting the GABAA Receptor: The Core Mechanism

Zopiclone acts as a Positive Allosteric Modulator on the GABAA receptor, an ion channel located in the central nervous system ( CNS). The molecule binds to a site distinct from the GABA binding site, modifying the receptor's conformation to enhance the effects of the endogenous GABA neurotransmitter, which results in a decrease in neural activity.

The Inhibitory Cascade and CNS Depression

The enhanced GABA signal triggers a cascade by driving an enhanced influx of negatively charged chloride ions into the neuron. This molecular change results in neuronal hyperpolarization—the core mechanism for widespread Central Nervous System ( CNS) depression—leading directly to a physiological state characterized by reduced neuronal firing and pronounced CNS depression.

Subunit Specificity and Physiological Outcome

Zopiclone demonstrates high affinity for GABAA receptors containing the alpha1 subunit. This modulation contributes to the suppression of neural circuits that promote wakefulness, resulting in a state of reduced arousal. This mechanism is subject to pharmacodynamic tolerance, as prolonged engagement can lead to functional changes in the GABAA receptor system, resulting in a constraint on the mechanism's continued physiological responsiveness.

How to Use Somnols: Official Administration Guidelines

Somnols (Zopiclone) is indicated for use according to established parameters concerning its administration, dosage, frequency, and treatment duration.

Administration and Dosage

The approved route for taking Somnols is oral administration. The medicine is typically available as a film-coated tablet in strengths including 3.75 mg and 7.5 mg.

The standard adult dose is 7.5 mg, taken as a single dose, and this is the maximum recommended daily amount that should not be exceeded. For certain patient groups, a lower initial dose of 3.75 mg is generally advised.

Administration Scope	Guideline (As per Official Labeling)
Route of Administration	Oral, swallowed whole with liquid.
Dosing Schedule	Single daily dose of 7.5 mg; maximum of 7.5 mg/day.
Timing in Relation to Meals	May be taken with or without food.
Age-Group Rules	Initial dose of 3.75 mg is recommended for older adults.

---

Frequency and Duration Protocol

The frequency is strictly defined as a single intake, once daily. The dose must be taken immediately before retiring for the night, only when the patient is able to dedicate approximately seven to eight hours for sleep. It is prohibited to take a second dose during the same night.

Somnols is approved for short-term use only. The total course of treatment, including any necessary period of gradual dose reduction, should not exceed four weeks. Continuation of treatment past this four-week limit requires a formal re-evaluation of the patient's condition.

Research evidence / Overview of Studies for Somnols (Zopiclone)

Evidence from Short-Term Clinical Trials

Somnols was studied for conditions characterized by fluctuating or episodic manifestations of insomnia. Research examining this medicine is primarily based on short-term, randomized controlled trials (RCTs). These are research studies where participants were randomly assigned to receive either Zopiclone, a reference treatment, or an inactive substance called a placebo. Research examined patients in trials typically lasting one to four weeks.

Studies monitored several key sleep outcomes related to systemic or functional imbalance, including the time it took participants to fall asleep (Sleep Onset Latency) and the Total Sleep Time achieved. They also monitored the amount of time participants spent awake after initially falling asleep (Wake After Sleep Onset). Research highlights changes measured during the study period. Studies reported measurements related to how symptoms evolved in the observed populations, including those compared to placebo.

The evidence describes research exploring short-term symptom patterns over defined time intervals. The short follow-up durations were limited, which means these studies offer primary insight into the immediate changes monitored during the study period, not long-term outcomes.

---

Studies Comparing Zopiclone to Placebo and Other Hypnotics

Research exploring short-term symptom changes for Somnols has frequently included a comparison group receiving a placebo. These comparisons are a standard component of regulatory review for evidence derived from settings with varying symptom burdens.

In addition to placebo, research examined Zopiclone in trials where it was assessed against a specific comparator agent used for sleep difficulties. These studies explored how symptoms evolved in the observed populations relative to those receiving other pharmacological options. Systematic reviews and meta-analyses were applied in studies examining patient-reported experiences, pooling the data from multiple trials to find consistent findings. Findings indicate that outcomes related to sleep metrics were monitored across these different comparison groups.

---

Research Gaps and Areas of Uncertainty

Evidence describes uncertainty related to long-term effects and outcomes. Due to the short duration of most controlled trials, long-term outcomes are not well characterized, and there is limited controlled data on the sustained benefits or patterns of use for many months or years. Evidence for extended use in those with conditions characterized by fluctuating or episodic manifestations remains limited.

Key Studies & References Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation

Common questions about Somnols (FAQ)

Q: What should I do if I miss a dose of Somnols?

A: Official information derived from regulatory sources advises that if a dose is missed at the scheduled bedtime, the patient should skip that dose completely. The subsequent dose should then be taken at the usual time the following night, as directed on the label. Regulatory documents state that taking two doses at the same time or an extra amount to compensate for a missed dose should be avoided.

Q: What are the signs of an overdose on Somnols and what should I do?

A: Signs of an overdose typically involve pronounced Central Nervous System (CNS) depression, a condition where the brain's activity slows down. Symptoms may include extreme drowsiness, confusion, shallow breathing, or a significant drop in blood pressure, and may potentially lead to a comatose state. If an overdose is suspected, official guidance strongly advises seeking immediate emergency medical attention.

Q: Can I split or crush the Somnols tablet before taking it?

A: No, regulatory documents state that the Somnols tablet must be swallowed whole with liquid. The medicine is manufactured to be taken as an intact tablet. Official information advises against splitting, crushing, or chewing the tablet before ingestion.

Q: Will I have a "hangover" or feel sleepy the next day after taking Somnols?

A: Official information indicates that Somnols can cause drowsiness or fatigue that may persist into the next day. This is due to its function as a central nervous system depressant. Because of the risk of next-day effects and psychomotor impairment, official guidance advises against driving or operating hazardous machinery for at least 12 hours after taking the medicine.

Official Storage and Disposal Instructions

Storage Component	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not store above 30 C or freeze.
Protection	Keep the medicine protected from light and moisture. Do not store in high-humidity areas, such as a bathroom.
Container	The medication must be kept in its original container and the cap must be kept tightly closed to protect the integrity of the tablet.
Child Safety	Store Somnols out of the sight and reach of children and pets, as is required for all prescription medications.
Disposal	Unused or expired tablets should be discarded using a drug take-back program. If a program is unavailable, mix the tablets with an unappealing substance (like used coffee grounds or dirt) and seal the mixture in a plastic bag before throwing it in the household trash. Do not flush down the toilet or pour into a drain.